Opens in a new tab
Tuesday, 17 November 2026
EVIDENCE. INTERPRETED.
Pharmacally

Lung Cancer

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in Lung Cancer

8 stories · every one Fact-Checked
Scientific illustration of investigational KRAS G12C inhibitor olomorasib combined with pembrolizumab in first-line KRAS G12C-mutant non-small cell lung cancer.Health TidingsLilly Reports Promising Results for Olomorasib in Lung CancerEli Lilly presented updated ESMO 2026 data showing antitumour activity with investigational olomorasib in first-line KRAS G12C-mutant non-small cell lung cancer.26 Oct 2026 · 4 min read
Fact-Checked
Divarasib targeted therapy concept illustrating KRAS G12C inhibition in advanced non-small cell lung cancerClinical TrialsRoche’s Divarasib Improves Survival in KRAS G12C Lung CancerRoche’s Phase III KRASCENDO 1 trial showed improved overall survival, progression-free survival and tumour response with investigational divarasib compared with sotorasib or adagrasib in previously treated KRAS G12C-mutated…26 Oct 2026 · 4 min read
Fact-Checked
Generate Biomedicines GB-0895 clinical posters ahead of ERS Congress 2026Clinical TrialsAstraZeneca and HUTCHMED Report Positive SAFFRON Phase III Results in MET-Driven Lung CancerSAFFRON Phase III showed significant progression-free and overall survival benefits with savolitinib plus osimertinib in MET-driven EGFR-mutated NSCLC. Written By…17 Aug 2026 · 3 min read
Fact-Checked
AstraZeneca licenses Zegfrovy (sunvozertinib) from Dizal to expand treatment options for EGFR exon 20 insertion-positive non-small cell lung cancer worldwide.Mergers & AcquisitionsAstraZeneca Licenses Zegfrovy from Dizal in Up to $1.5 Billion Deal to Expand EGFR-Mutated Lung Cancer PortfolioAstraZeneca has licensed global rights to Zegfrovy (sunvozertinib) from Dizal in a deal valued at up to $1.5 billion.14 Jul 2026 · 3 min read
Fact-Checked
Illustration of Alzheimer's disease tau pathology showing Eisai's investigational anti-tau antibody etalanetug (E2814) reducing the plasma biomarker eMTBR-tau243 presented at AAIC 2026.Health TidingsMHRA Validates Eisai’s Taletrectinib for ROS1-Positive Lung CancerEisai has reached another regulatory milestone for taletrectinib as the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) validated its Marketing Authorisation Application for adults with advanced ROS1-positive…26 Jun 2026 · 3 min read
Fact-Checked
Gemini_Generated_Image_med8uvmed8uvmed8Health TidingsLantern Reports Durable LP-300 Responses in EGFR L858R Lung CancerLantern Pharma announced updated Phase 2 HARMONIC trial results demonstrating prolonged progression-free survival, durable responses, and a favorable safety profile for LP-300 in combination with carboplatin and pemetrexed…2 Jun 2026 · 3 min read
Fact-Checked
Doctor reviews chest x-ray results with patient in a medical office.Health TidingsFDA Takes Up Zipalertinib Application for Lung CancerThe FDA has accepted for review the NDA for zipalertinib in patients with EGFR exon 20 insertion–mutated NSCLC following platinum-based chemotherapy.29 Apr 2026 · 2 min read
Fact-Checked
pexels-shvetsa-3900427New Drug ApprovalMHRA Approves Sevabertinib for HER2+ Lung CancerSevabertinib (Hyrnuo) receives MHRA approval for adults with advanced HER2-mutant Non-small cell lung cancer after prior therapy, showing a 71% response rate in clinical studies.5 Apr 2026 · 2 min read
Fact-Checked
Page 1 of 1